Blood Market by Product (Whole Blood Collection and Processing, Source Plasma Collection, Blood Typing Products, and Blood Screening Products) and End User (Blood & Blood Component Bank, Diagnostic Laboratories, Ambulatory Surgical Centers, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-18
- Report ID: 18208
- Pages: 261
-
Format:
The blood market accounted for $7,201 million in 2020, and is expected to reach $10,253 million by 2027, registering a CAGR of 4.5% from 2020 to 2027.
Blood is vital for life and is required for normal functioning of the human body. Furthermore, bone marrow is responsible for the production of blood cells in the body. However, various medical conditions can lead to altered level of blood, which can be fatal for a patient. For instance, medical conditions such as chronic kidney diseases, cancer, and hemophilia B require blood transfusions for treatment. Moreover, in event of a trauma, which causes injury to a patient, blood transfusion is might be required for treatment based on the nature of the injury. Similarly, surgeries can also lead to major blood loss leading to the need for blood transfusions. Furthermore, plasma is a major content of blood and low level of plasma in the body can hamper normal functioning. Thus, patients who suffer from medical conditions such as liver diseases lead to lower plasma level requiring plasma transfusions. Thus, collection of blood is a necessary task and requires the use of reagents and blood collection systems. Moreover, the collected blood is subjected to screening, which further requires use of systems and reagents. This collected and screened blood is then circulated to various end users such as blood and blood component banks, diagnostic laboratories, ambulatory surgical centers, and hospitals.
Growth of the blood market is driven by factors such as surge in demand for blood and plasma across the globe and rise in geriatric population worldwide. In addition, increase in blood and plasma donations across the globe and favorable government regulations for blood screening are some other factors that boost the growth of the market.
Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives growth of the blood market. However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Conversely, developing economies offer lucrative growth opportunities for the market growth.
The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. Furthermore, all these segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. In addition, the blood typing products are further bifurcated into blood typing systems, blood typing reagents. The blood screening products are divided into blood screening systems, and blood screening reagents.
On the basis of end user, the market is divided into blood and blood component bank, diagnostic laboratories, ambulatory surgical centers, hospitals, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., CSL Limited (CSL Behring), F. Hoffmann-La Roche Ltd., Grifols International SA, Haemonetics Corporation, Merck & Co., Inc., Novo Nordisk A/S, Ortho Clinical Diagnostics, and Terumo Corporation (Terumo BCT, Inc.) are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global blood market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Product
o Whole Blood Collection and Processing
Whole Blood Collection Systems
Whole Blood Collection Consumables
o Source Plasma Collection
Source Plasma Collection Systems
Source Plasma Collection Consumables
o Blood Typing Products
Blood Typing Systems
Blood Typing Reagents
o Blood Screening Products
Blood Screening Systems
Blood Screening Reagents
By End User
o Blood & Blood Component Bank
o Diagnostic Laboratories
o Ambulatory Surgical Centers
o Blood And Blood Component Bank
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Rest of Europe
o Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
Abbott Laboratories
Bio-Rad Laboratories, Inc.
CSL Limited (CSL Behring).
F. Hoffmann-La Roche Ltd.
Grifols International SA
Haemonetics Corporation
Merck & Co., Inc.
Novo Nordisk A/S
Ortho Clinical Diagnostics
Terumo Corporation (Terumo BCT, Inc.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Fresenius Kabi
Qiagen N.V.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.3.Key forces shaping blood industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in demand for blood and other blood related products across the globe
3.4.1.2.Rise in geriatric population across the globe
3.4.1.3.Surge in blood donations and plasma donations across the globe
3.4.1.4.Favorable government regulations for blood screening
3.4.1.5.Advancements in blood transfusion and blood screening instruments
3.4.2.Restraints
3.4.2.1.High cost of advanced blood collection devices
3.4.2.2.Lack of skilled laboratory professionals
3.4.3.Opportunities
3.4.3.1.Developing economies offer lucrative growth opportunities
3.4.4.Impact Analysis
3.5.Blood Therapeutics
3.5.1.Key market trends, growth factors, and opportunities
3.5.2.Market size and forecast, by product
3.5.2.1.Intravenous Immunoglobulin
3.5.2.1.1.Market size and forecast
3.5.2.2.Factor IX
3.5.2.2.1.Market size and forecast
3.5.2.3.Factor VIII
3.5.2.3.1.Market size and forecast
3.5.2.4.Albumin
3.5.2.4.1.Market size and forecast
3.5.2.5.Hyperimmune
3.5.2.5.1.Market size and forecast
3.5.2.6.Others
3.5.2.6.1.Market size and forecast
3.5.3.Market size and forecast, by region
CHAPTER 4:BLOOD MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Whole blood collection and processing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Whole Blood Collection and Processing Systems
4.2.2.1.1.Market size and forecast
4.2.2.1.2.Market size and forecast, by region
4.2.2.2.Whole Blood Collection and Processing Consumables
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Source plasma collection
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Source Plasma Collection Systems
4.3.2.1.1.Market size and forecast
4.3.2.1.2.Market size and forecast, by region
4.3.2.2.Source Plasma Collection Consumables
4.3.2.2.1.Market size and forecast
4.3.2.2.2.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Blood typing products
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Blood Typing Systems
4.4.2.1.1.Market size and forecast
4.4.2.1.2.Market size and forecast, by region
4.4.2.2.Blood Typing Reagents
4.4.2.2.1.Market size and forecast
4.4.2.2.2.Market size and forecast, by region
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Blood screening products
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Blood Screening Systems
4.5.2.1.1.Market size and forecast
4.5.2.1.2.Market size and forecast, by region
4.5.2.2.Blood Screening Reagents
4.5.2.2.1.Market size and forecast
4.5.2.2.2.Market size and forecast, by region
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:BLOOD MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Blood and blood component bank
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Diagnostic laboratories
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ambulatory surgical centers
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Hospitals
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:BLOOD MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. blood market size and forecast, by product
6.2.2.1.2.U.S. blood market size and forecast, by end user
6.2.2.2.Canada
6.2.2.2.1.Canada blood market size and forecast, by product
6.2.2.2.2.Canada blood market size and forecast, by end user
6.2.2.3.Mexico
6.2.2.3.1.Mexico blood market size and forecast, by product
6.2.2.3.2.Mexico blood market size and forecast, by end use
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by end user
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany blood market size and forecast, by product
6.3.2.1.2.Germany blood market size and forecast, by end user
6.3.2.2.France
6.3.2.2.1.France blood market size and forecast, by product
6.3.2.2.2.France blood market size and forecast, by end user
6.3.2.3.UK
6.3.2.3.1.UK blood market size and forecast, by product
6.3.2.3.2.UK blood market size and forecast, by end user
6.3.2.4.Italy
6.3.2.4.1.Italy blood market size and forecast, by product
6.3.2.4.2.Italy blood market size and forecast, by end user
6.3.2.5.Spain
6.3.2.5.1.Spain blood market size and forecast, by product
6.3.2.5.2.Spain blood market size and forecast, by end user
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe blood market size and forecast, by product
6.3.2.6.2.Rest of Europe blood market size and forecast, by end user
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by end user
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan blood market size and forecast, by product
6.4.2.1.2.Japan blood market size and forecast, by end user
6.4.2.2.China
6.4.2.2.1.China blood market size and forecast, by product
6.4.2.2.2.China blood market size and forecast, by end user
6.4.2.3.Australia
6.4.2.3.1.Australia blood market size and forecast, by product
6.4.2.3.2.Australia blood market size and forecast, by end user
6.4.2.4.India
6.4.2.4.1.India blood market size and forecast, by product
6.4.2.4.2.India blood market size and forecast, by end user
6.4.2.5.South Korea
6.4.2.5.1.South Korea blood market size and forecast, by product
6.4.2.5.2.South Korea blood market size and forecast, by end user
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific blood market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific blood market size and forecast, by end user
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by end user
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil blood market size and forecast, by product
6.5.2.1.2.Brazil blood market size and forecast, by end user
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia blood market size and forecast, by product
6.5.2.2.2.Saudi Arabia blood market size and forecast, by end user
6.5.2.3.South Africa
6.5.2.3.1.South Africa blood market size and forecast, by product
6.5.2.3.2.South Africa blood market size and forecast, by end user
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA blood market size and forecast, by product
6.5.2.4.2.Rest of LAMEA blood market size and forecast, by end user
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.1.2.1. Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BIO-RAD LABORATORIES, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CSL LIMITED (CSL BEHRING)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.F. HOFFMANN-LA ROCHE LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS INTERNATIONAL SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.HAEMONETICS CORPORATION
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MERCK & CO., INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.NOVO NORDISK A/S
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.ORTHO CLINICAL DIAGNOSTICS
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments
7.10.TERUMO CORPORATION (TERUMO BCT, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
